South Korea is expected to mass-produce commercial COVID-19 antibody-based treatment later in September.
The deputy director of the Korea Centres for Disease Control and Prevention, Kwon Jun-wook, said this on Tuesday.
The country is currently analysing the results of phase 1 clinical trial of the antibody-based treatment, which was approved by the Ministry of Food and Drug Safety on July 17, and reviewing the phase 2, Kwon added.
As for blood plasma-based treatment, the health authorities skipped phase one of clinical trials, as the therapy itself is well-known and considered to be safe.
The country will start producing the blood plasma material for the phase 2 trial on Tuesday, while the supply of the substance will be completed in mid-October, Mr Kwon noted.
In total, clinical trials for 14 coronavirus treatments and two vaccines are currently underway in South Korea.
Support PREMIUM TIMES' journalism of integrity and credibility
Good journalism costs a lot of money. Yet only good journalism can ensure the possibility of a good society, an accountable democracy, and a transparent government.
For continued free access to the best investigative journalism in the country we ask you to consider making a modest support to this noble endeavour.
By contributing to PREMIUM TIMES, you are helping to sustain a journalism of relevance and ensuring it remains free and available to all.
TEXT AD: To advertise here . Call Willie +2347088095401...